middle.news
Cyclopharm’s US Growth Fuels Record Half-Year Revenue of $17.5 Million
8:09am on Monday 24th of August, 2026 AEST
•
Healthcare
Read Story
Cyclopharm’s US Growth Fuels Record Half-Year Revenue of $17.5 Million
8:09am on Monday 24th of August, 2026 AEST
Key Points
Record $17.5m revenue up 14%, driven by 74% US growth
US revenue-generating sites doubled to 70, pipeline at 1,684 locations
New US guidelines name Technegas® as generally preferred agent
Net loss widens to $8.8m due to US investment and R&D ramp-up
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Cyclopharm (ASX:CYC)
OPEN ARTICLE